Frontage To Launch Study for China Firm

Frontage has successfully filed an Investigational New Drug (IND) on behalf of Zhejiang Hisun Pharmaceutical Co. to initiate an early phase clinical study for HS-25, a cholesterol-lowering compound to treat hypercholesterolemia and nephrotic hyperlipidemia.
 
As the U.S. regulatory agent for Hisun, Frontage supported the HS-25 IND filing with drug development and regulatory consulting services, including CMC and pharmaceutical toxicology, plus the clinical development plan and protocols. Frontage also communicated with the FDA from the pre-IND meeting through the IND filing and post-IND discussions. Frontage will conduct the Phase I trial and other clinical pharmacology studies for HS-25 at its U.S. clinical center.